Julius Knowles - 01 Nov 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
01 Nov 2021
Net transactions value
-$2,007,129
Form type
4
Filing time
03 Nov 2021, 19:04:35 UTC
Previous filing
21 Oct 2021
Next filing
03 Dec 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Sale $295,335 -7,057 -1.6% $41.85 421,041 01 Nov 2021 See footnote F1, F2, F3
transaction KROS Common Stock Sale $192,468 -4,599 -1.6% $41.85 284,557 01 Nov 2021 See footnote F1, F2, F4
transaction KROS Common Stock Sale $311,860 -7,350 -1.7% $42.43 413,691 01 Nov 2021 See footnote F1, F3, F5
transaction KROS Common Stock Sale $203,537 -4,797 -1.7% $42.43 279,760 01 Nov 2021 See footnote F1, F4, F5
transaction KROS Common Stock Sale $136,909 -3,252 -0.79% $42.10 410,439 02 Nov 2021 See footnote F1, F3, F6
transaction KROS Common Stock Sale $89,252 -2,120 -0.76% $42.10 277,640 02 Nov 2021 See footnote F1, F4, F6
transaction KROS Common Stock Sale $65,335 -1,518 -0.37% $43.04 408,921 02 Nov 2021 See footnote F1, F3, F7
transaction KROS Common Stock Sale $42,653 -991 -0.36% $43.04 276,649 02 Nov 2021 See footnote F1, F4, F7
transaction KROS Common Stock Sale $252,691 -6,067 -1.5% $41.65 402,854 03 Nov 2021 See footnote F1, F3, F8
transaction KROS Common Stock Sale $164,809 -3,957 -1.4% $41.65 272,692 03 Nov 2021 See footnote F1, F4, F8
transaction KROS Common Stock Sale $152,693 -3,597 -0.89% $42.45 399,257 03 Nov 2021 See footnote F1, F3, F9
transaction KROS Common Stock Sale $99,588 -2,346 -0.86% $42.45 270,346 03 Nov 2021 See footnote F1, F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9).
F3 The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4 The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive.